In 264 patients evaluated with Holter monitors, numerically more cilostazol-treated patients had increases in ventricular premature beats and non-sustained ventricular tachycardia cilostazol overdosis events than did placebo-treated the increases were not dose-related. The most commonly reported adverse events, occurring in of patients treated with Pletal 50 or 100 mg. Cilostazol inhibits platelet aggregation induced by variety of different stimuli including ADP, collagen, arachidonic acid, epinephrine, thromboxane A2, platelet activating factor, and shear stress. The corresponding changes in the placebo group were 10 to 41. The most commonly reported adverse events, occurring in of patients treated with Cilostazol 50 or 100 mg. Use with Clopidogrel There is limited information with respect to the efficacy or safety of the concurrent use of cilostazol and clopidogrel, platelet-aggregation inhibiting drug indicated for use in patients with peripheral arterial disease.